摘要：目的检测终末糖基化产物(AGEs)在尿毒症患者血中的水平及在血管壁和腹膜上的表达及探讨其可能意义。方法用酶联免疫法(EUSA)检测尿毒症患者血中AGEs的水平；用免疫组织化学方法在血液透析患者检测其血管壁上AGEs的表达，及腹膜透析患者腹膜上AGEs和层粘蛋白(laminin)的表达。结果尿毒症患者血中AGEs水平明显高于肾功能正常者，且各种透析治疗均不能地降低患者体内AGEs水平。AGEs在血液透析患者血管壁有明显沉积；行腹膜透析一段时间后腹膜AGEs及laminin的表达也明显升高，两者呈明显正相关，且与腹透时间也有相关性。结论血中高浓度的AGEs及其在血管壁的沉积可能与尿毒症患者心血管并发症有关；腹膜透析患者腹膜上AGEs及laminin沉积可能是腹膜硬化及失超滤的原因之一。

The serum level of advanced glycosylation end products and its expression in the vascular wall and peritoneum of uremic patients

lU Fuming,GU Kangxia,GUO Xiaomin(Department of Nepbrology, Huashan Hospital, Shanghai Medical University, Shanghai 200040, China)

Abstract：Objective To determine the serum level of advanced glycosylation end products(AGEs) of uremia and its expression in the vascular wall and peritoneum of dialysis patient, meanwhile to explore its possible significance. Methods Using the ELISA method to determine the sermn level of AGEs of uremia; using immunohistochemical method to examine the expression of AGEs in the vascular wall of uremia patients undergoing hemodialysis and the expression of AGEs and laminin in the peritoneum of uremic patients undergoing peritoneal dialysis. Results The AGEs level of uremic patients was obviously higher than that in the normal. No kind of dialysis could elear it well. AGEs accumulated obviously in the vassular wall of hemodialysis patients. After CAPD the expression of AGEs and laminin in the peritonemn was significantly strong. There was an obviously positive correlation between AGEs and laminin, so between these two and the time of peritoneal dialysis. Conclusions The high serum level of AGEs and its accumulation in the vascular wall may relate with the high incidence of cardic diseases of the uremia. Accumulation of AGEs and laminin in the peritoneum of patients undergoing peritoneal dialysis may be one of the reasons causing peritoneum sclerosis and dysultrafiltration

Keywords：Advanced glycosylation end products; urecmia; Vascular wall; Peritoneum; Laminin参考文献：

［1］David R, Damiel G, John A, et al. Millard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest, 1993, 91: 2470-2478.

［2］Brownlee M, Rami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med, 1988, 318: 1315-1321.

［3］Deyn P, Mrsgau B, Lornoy W, et al. Serum gunidino compound levels and the influence of single hemodialysis in uremic patients undergoing maintenance hemodialysis. Nephron, 1987, 45: 291-295.

［4］Ateshkadi A, Johnson C, Founds H, et al. Serum AGE in patients on hemodialysis and cAPD. Petit Dial Int, 1995, 15: 129-133.

［5］Shi D, Ann M, Anderson G, et al. Enhanced cellular oxidant stress by the interaction of AGE with their receptors/binding proteins. J Biol chem, 1994, 269: 9889-9897.

［6］Yoshiyuki N, Yasuhiro H, Toshihiko N, et al. Immunohistochemical location of AGE in coronary atheroma and cardiac tissue in diabetes mellitus. Am J pathol, 1993, 143: 1649-1656.

［7］Yamda K, Miyahara Y, Hamaguchi K, et al. Immunoistochemical study of human AGE in chronic renal failure. Clin nephrol, 1994, 42: 354-361.

［8］Aristidis S, Lorrel A, Jay E, et al. Laminin alteration after in vitro nonenzymatic glycosylation. Diabetes, 1990, 39: 808-814.

［9］Edmund J, William R, Anne B. In vitro formation of advanced glycation end products in peritoneal dialysis fluid. Kidney int, 1995, 47: 1768-1774.

收稿日期：2000-01-05